1. Home
  2. CYTK vs ELPC Comparison

CYTK vs ELPC Comparison

Compare CYTK & ELPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYTK
  • ELPC
  • Stock Information
  • Founded
  • CYTK 1997
  • ELPC 1954
  • Country
  • CYTK United States
  • ELPC Brazil
  • Employees
  • CYTK N/A
  • ELPC N/A
  • Industry
  • CYTK Biotechnology: Pharmaceutical Preparations
  • ELPC Electric Utilities: Central
  • Sector
  • CYTK Health Care
  • ELPC Utilities
  • Exchange
  • CYTK Nasdaq
  • ELPC Nasdaq
  • Market Cap
  • CYTK 5.6B
  • ELPC 6.1B
  • IPO Year
  • CYTK 2004
  • ELPC N/A
  • Fundamental
  • Price
  • CYTK $37.73
  • ELPC $7.76
  • Analyst Decision
  • CYTK Buy
  • ELPC
  • Analyst Count
  • CYTK 14
  • ELPC 0
  • Target Price
  • CYTK $70.92
  • ELPC N/A
  • AVG Volume (30 Days)
  • CYTK 1.4M
  • ELPC 4.6K
  • Earning Date
  • CYTK 08-07-2025
  • ELPC 01-01-0001
  • Dividend Yield
  • CYTK N/A
  • ELPC 5.07%
  • EPS Growth
  • CYTK N/A
  • ELPC 31.95
  • EPS
  • CYTK N/A
  • ELPC 0.17
  • Revenue
  • CYTK $19,218,000.00
  • ELPC $4,033,509,015.00
  • Revenue This Year
  • CYTK $27.08
  • ELPC N/A
  • Revenue Next Year
  • CYTK $652.09
  • ELPC $5.55
  • P/E Ratio
  • CYTK N/A
  • ELPC $12.05
  • Revenue Growth
  • CYTK 412.21
  • ELPC 6.92
  • 52 Week Low
  • CYTK $29.31
  • ELPC $5.04
  • 52 Week High
  • CYTK $61.38
  • ELPC $8.87
  • Technical
  • Relative Strength Index (RSI)
  • CYTK 55.97
  • ELPC 38.51
  • Support Level
  • CYTK $36.71
  • ELPC $7.85
  • Resistance Level
  • CYTK $38.54
  • ELPC $8.06
  • Average True Range (ATR)
  • CYTK 1.33
  • ELPC 0.15
  • MACD
  • CYTK -0.03
  • ELPC -0.06
  • Stochastic Oscillator
  • CYTK 61.38
  • ELPC 21.88

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About ELPC Companhia Paranaense de Energia (COPEL) (each representing four (4))

Cia Paranaense De Energia Copel is engaged in the areas of generation, transmission, commercialization and distribution of energy. It operates a comprehensive and effective electrical system with its own generating plants, transmission lines, substations, electrical lines and grids of the distribution system. The company's reportable segments include Power generation and transmission, Power distribution, GAS, Power sale, Services, and Holding. The majority of its revenue is generated from the Power generation and transmission segment under which it produces electricity from hydraulic, wind, and thermal projects and provides services of transmission and transformation of electric power and other related services.

Share on Social Networks: